echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Renfu Pharmaceutical Memantine Hydrochloride Sustained-Release Capsules Received U.S. FDA Approval Number

    Renfu Pharmaceutical Memantine Hydrochloride Sustained-Release Capsules Received U.S. FDA Approval Number

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 7, Renfu Medicine issued an announcement stating that its holding subsidiary, Yichang Renfu, had recently received an approval number from the US FDA for memantine hydrochloride sustained-release capsules.


    Memantine hydrochloride sustained-release capsules are used to treat moderate to severe Alzheimer's disease dementia.


    Allergan Company holds seven patents of Memantine Hydrochloride Sustained Release Capsules.


    According to statistics from IQVIA, the total sales of the drug in the US market in 2020 will be approximately 61 million U.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.